Endometriosis – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Endometriosis – Pipeline Review, H1 2018’, provides an overview of the Endometriosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Endometriosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Endometriosis

– The report reviews pipeline therapeutics for Endometriosis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Endometriosis therapeutics and enlists all their major and minor projects

– The report assesses Endometriosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Endometriosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Endometriosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Endometriosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Addex Therapeutics Ltd

Astellas Pharma Inc

Bayer AG

ElexoPharm GmbH

EndoCeutics Inc

Enteris BioPharma Inc

Evotec AG

Forendo Pharma Ltd

Immunitor Inc

Kissei Pharmaceutical Co Ltd

Luye Pharma Group Ltd

Nippon Shinyaku Co Ltd

Ogeda SA

Philogen SpA

Repros Therapeutics Inc

SK Chemicals Co Ltd

Takeda Pharmaceutical Co Ltd

ValiRx Plc

Viramal Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Endometriosis Overview 7

Endometriosis Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 12

Products under Development by Companies 13

Products under Development by Universities/Institutes 16

Endometriosis Therapeutics Assessment 17

Assessment by Target 17

Assessment by Mechanism of Action 20

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Endometriosis Companies Involved in Therapeutics Development 27

AbbVie Inc 27

Addex Therapeutics Ltd 27

Astellas Pharma Inc 28

Bayer AG 28

ElexoPharm GmbH 29

EndoCeutics Inc 29

Enteris BioPharma Inc 30

Evotec AG 30

Forendo Pharma Ltd 31

Immunitor Inc 31

Kissei Pharmaceutical Co Ltd 31

Luye Pharma Group Ltd 32

Nippon Shinyaku Co Ltd 32

Ogeda SA 33

Philogen SpA 33

Repros Therapeutics Inc 33

SK Chemicals Co Ltd 34

Takeda Pharmaceutical Co Ltd 34

ValiRx Plc 35

Viramal Ltd 35

Endometriosis Drug Profiles 36

acolbifene hydrochloride + GnRH Agonist + prasterone Drug Profile 36

BAY-1128688 Drug Profile 37

BAY-1158061 Drug Profile 38

BAY-1817080 Drug Profile 39

BAY-1834845 Drug Profile 40

danazol Drug Profile 41

Drug 1 for Endometriosis Drug Profile 42

Drug 2 for Endometriosis Drug Profile 43

Drug 3 for Endometriosis Drug Profile 44

Drug 4 for Endometriosis Drug Profile 45

Drug for Endometriosis Drug Profile 46

Drug to Antagonize P2X3 for Endometriosis Drug Profile 47

Drug to Inhibit C-Jun for Endometriosis Drug Profile 48

EC-304 Drug Profile 49

EC-313 Drug Profile 50

elagolix sodium Drug Profile 51

fezolinetant Drug Profile 58

FP-5677 Drug Profile 61

goserelin ER Drug Profile 62

KLH-2109 Drug Profile 63

leuprolide Drug Profile 66

MIA-602 Drug Profile 68

NHP-07 Drug Profile 70

NS-580 Drug Profile 71

opigolix Drug Profile 72

PGL-2001 Drug Profile 73

progesterone Drug Profile 74

Recombinant Protein for Endometriosis, Ovarian Hyperstimulation Syndrome and Polycystic Ovarian Syndrome Drug Profile 75

relugolix Drug Profile 76

SKI-2670 Drug Profile 83

Small Molecule to Antagonize FSH Receptor and LH Receptor for Women's Health Drug Profile 84

Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Oncology and Uterine Fibroids Drug Profile 85

Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis Drug Profile 86

Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis Drug Profile 87

Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers Drug Profile 88

Small Molecules to Inhibit CD147 for Arthritis, Endometriosis, Immunology and Oncology Drug Profile 89

Small Molecules to Inhibit HSD17B1 for Endometriosis Drug Profile 90

SP-011 Drug Profile 91

SP-012 Drug Profile 92

SR-16234 Drug Profile 93

Stem Cell Therapy for Asherman's Syndrome and Endometrial Atrophy Drug Profile 94

Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology Drug Profile 95

telapristone acetate Drug Profile 96

tetravil Drug Profile 105

TOT-206 Drug Profile 107

triptorelin acetate ER Drug Profile 108

V-Endo Drug Profile 109

VAL-301 Drug Profile 110

vilaprisan Drug Profile 111

VPE-001 Drug Profile 113

Endometriosis Dormant Projects 114

Endometriosis Discontinued Products 116

Endometriosis Product Development Milestones 117

Featured News & Press Releases 117

Appendix 129

Methodology 129

Coverage 129

Secondary Research 129

Primary Research 129

Expert Panel Validation 129

Contact Us 129

Disclaimer 130

List of Tables

List of Tables

Number of Products under Development for Endometriosis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Endometriosis Pipeline by AbbVie Inc, H1 2018

Endometriosis Pipeline by Addex Therapeutics Ltd, H1 2018

Endometriosis Pipeline by Astellas Pharma Inc, H1 2018

Endometriosis Pipeline by Bayer AG, H1 2018

Endometriosis Pipeline by ElexoPharm GmbH, H1 2018

Endometriosis Pipeline by EndoCeutics Inc, H1 2018

Endometriosis Pipeline by Enteris BioPharma Inc, H1 2018

Endometriosis Pipeline by Evotec AG, H1 2018

Endometriosis Pipeline by Forendo Pharma Ltd, H1 2018

Endometriosis Pipeline by Immunitor Inc, H1 2018

Endometriosis Pipeline by Kissei Pharmaceutical Co Ltd, H1 2018

Endometriosis Pipeline by Luye Pharma Group Ltd, H1 2018

Endometriosis Pipeline by Nippon Shinyaku Co Ltd, H1 2018

Endometriosis Pipeline by Ogeda SA, H1 2018

Endometriosis Pipeline by Philogen SpA, H1 2018

Endometriosis Pipeline by Repros Therapeutics Inc, H1 2018

Endometriosis Pipeline by SK Chemicals Co Ltd, H1 2018

Endometriosis Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018

Endometriosis Pipeline by ValiRx Plc, H1 2018

Endometriosis Pipeline by Viramal Ltd, H1 2018

Endometriosis Dormant Projects, H1 2018

Endometriosis Dormant Projects, H1 2018 (Contd..1), H1 2018

Endometriosis Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Endometriosis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports